AMSBIO: Custom CAR-T Development Service

Hits:673   Date: 1/30/2020

AMSBIO announces a Custom Chimeric Antigen Receptor T cell (CAR-T) service designed to take advantage of the astonishing clinical breakthroughs achieved with CAR-T cells in various hematological malignancies.

CAR-T cell therapy is a groundbreaking immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR). The CAR-T cell is an effector T cell that recognizes and eliminates specific cancer cells, independent of major histocompatible complex molecules. The CAR-T cell therapies have been widely used in the treatment of hematological malignancies, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, lymphoma, and multiple myeloma.

Drawing upon its expertise in monoclonal antibody development (rabbit and mouse), AMSBIO can help you design, plan and execute your CAR-T study, whether you are in the preclinical, clinical or proof of concept stage. The AMSBIO CAR-T platform is highly adaptable to your needs and starting materials, as we can start with a target molecule (Phase I) or antibody (Phase II). 

As part of their custom CAR-T development service - AMSBIO construct the single chain variable fragment (ScFv), transfer it into a CAR lentivector of your choice, make lentivirus and transduce activated human (or mouse) T cells. After the CAR-T cells proliferate, the cytotoxicity is measured in a real time assay, CAR expression analyzed and cytokine production quantified.

For further information on the new Custom CAR-T development service please visit www.amsbio.com/car-t-service.aspx or contact AMSBIO on +44-1235-828200 / +1-617-945-5033 / email info@amsbio.com.

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. 

For drug discovery research, AMSBIO offers assays, recombinant proteins and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognised as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications these include high quality solutions for viral delivery (lentivirus, adenovirus and adeno-associated virus) in addition to GMP cryopreservation technology.

---------------------

Worldwide HQ 

AMS Biotechnology (AMSBIO)
184 Milton Park
Abingdon
Oxon OX14 4SE
UK
Tel: +44-1235-828200
Fax: +44-1235-820482
Email: info@amsbio.com 
Web www.amsbio.com
 
North American HQ
 
AMSBIO LLC
1035 Cambridge Street
Cambridge
MA 02141
USA
Tel: +1.617.945.5033 
Tel:  +1.800.987.0985 (toll free)
Email: info@amsbio.com 
Web www.amsbio.com